Award recordCONTRACT

GENZYME CORPORATION

PIID VA24312P0995· VHA· 243-NETWORK CONTRACTING OFFICE 03· Q301 · MEDICAL- LABORATORY TESTING· FY2012· $136,000 net obligations· UEI X2XMAQLR9DA8· MA

Description

AMENDMET INCREASE IS FOR $48,000 FOR THE CONTINUATION OF LABORATORY SERVICES THAT WILL BE USED TO ASSIST IN THE TREATMENT OF OUR VETERANS.

Base award description: LABORATORY COST-PER-TEST

First action · last action
2011-11-22 · 2012-09-28
Transactions
2
First transaction's obligation
$88,000
Base + all options value (sum of deltas)
$136,000
Extent competed
NOT COMPETED UNDER SAP
Other than full & open authority
AUTHORIZED BY STATUTE
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
621511 · MEDICAL LABORATORIES

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$136,000$0Base award · 2011-11-22 · this action $88,000 · running total $88,000Modification 1 · 2012-09-28 · this action $48,000 · running total $136,000
  • Base2011-11-22+$88,000= $88,000
  • Mod 12012-09-28+$48,000= $136,000
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2011-11-22+$88,000$88,000LABORATORY COST-PER-TEST
Mod 1· FUNDING ONLY ACTION2012-09-28+$48,000$136,000AMENDMET INCREASE IS FOR $48,000 FOR THE CONTINUATION OF LABORATORY SERVICES THAT WILL BE USED TO ASSIST IN TH…

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI X2XMAQLR9DA8)

AwardOffice · PSC / listingNet obligationsFY
36E79724A0018NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2024
36C26124N0260261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS$11,882FY2024
36C26023F0186260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS$144,553FY2023
36C26223F0045262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS$246,001FY2023
36C26223F0022262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS$266,652FY2023
36C26222F0606262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS$20,049FY2022

Other recipients under Q301 from 243-NETWORK CONTRACTING OFFICE 03 (most recent first)

AwardRecipientOfficeNet obligationsFY
VA24316P1654VERACYTE, INC.243-NETWORK CONTRACTING OFFICE 03$11,749FY2016
VA24316P1048DATA INNOVATIONS LLC243-NETWORK CONTRACTING OFFICE 03$12,500FY2016
VA24315C0137TRIANGLE MANIFOLD SERVICES, INC.243-NETWORK CONTRACTING OFFICE 03$11,700FY2015
VA24315P2997VERACYTE, INC.243-NETWORK CONTRACTING OFFICE 03$0FY2015
VA24315J2661ROCHE DIAGNOSTICS CORPORATION243-NETWORK CONTRACTING OFFICE 03$105,071FY2015

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24312P0995_3600_-NONE-_-NONE- · retrieved 2026-09-26.